Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI1773

Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.

L H O'Connor, L C Erway, C A Vogler, W S Sly, A Nicholes, J Grubb, S W Holmberg, B Levy, and M S Sands

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by O'Connor, L. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Erway, L. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Vogler, C. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Sly, W. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Nicholes, A. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Grubb, J. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Holmberg, S. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Levy, B. in: PubMed | Google Scholar

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Find articles by Sands, M. in: PubMed | Google Scholar

Published April 1, 1998 - More info

Published in Volume 101, Issue 7 on April 1, 1998
J Clin Invest. 1998;101(7):1394–1400. https://doi.org/10.1172/JCI1773.
© 1998 The American Society for Clinical Investigation
Published April 1, 1998 - Version history
View PDF
Abstract

Mucopolysaccharidosis type VII (MPS VII; Sly syndrome) is one of a group of lysosomal storage diseases that share many clinical features, including mental retardation and hearing loss. Lysosomal storage in neurons of the brain and the associated behavioral abnormalities characteristic of a murine model of MPS VII have not been shown to be corrected by either bone marrow transplantation or gene therapy. However, intravenous injections of recombinant beta-glucuronidase initiated at birth reduce the pathological evidence of disease in MPS VII mice. In this study we present evidence that enzyme replacement initiated at birth improved the behavioral performance and reduced hearing loss in MPS VII mice. Enzyme-treated MPS VII mice performed similarly to normal mice and significantly better than mock- treated MPS VII mice in every phase of the Morris Water Maze test. In addition, the auditory function of treated MPS VII mice was dramatically improved, and was indistinguishable from normal mice. These data indicate that some of the learning, memory, and hearing deficits can be prevented in MPS VII mice if enzyme replacement therapy is initiated early in life. These data also provide functional correlates to the biochemical and histopathological improvements observed after enzyme replacement therapy.

Version history
  • Version 1 (April 1, 1998): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts